E1325. An In-Depth Look into Molecular Imaging and Theranostics in Prostate Cancer
Authors
Hatem Al Kashroom;
SUNY Upstate Medical University
Leen Alkukhun;
SUNY Upstate Medical University
Ryan Baker;
SUNY Upstate Medical University
Amr Wardeh;
SUNY Upstate Medical University
Meghan Stanton;
SUNY Upstate Medical University
Alyssa Ionno;
SUNY Upstate Medical University
Mary Mcgrath;
SUNY Upstate Medical University
Background
Recent advancements in the fields of molecular imaging and theranostics resulted in the evolution of multiple molecular imaging probes targeting prostate cancer. Prostate cancer is the most common malignancy in men, aside from cutaneous cancers. The purpose of this educational exhibit is to discuss the currently available and experimental molecular imaging agents, their properties, normal distribution, and their pitfalls, with examples, mainly from our institution as well as a few images from the literature. We will also discuss currently FDA-approved theranostic agents and their indications, as well as newer agents currently under development. Our focus will be directed on PET/CT imagining for prostate cancer.
Educational Goals / Teaching Points
Discuss the available probes for molecular imaging of prostate cancer. Discuss the specifications and advantages for each FDA-approved molecular imaging probe.Discuss upcoming molecular imaging probes and those under investigations for prostate cancer. Discuss the available theranostic agents and those under investigation.
Key Anatomic/Physiologic Issues and Imaging Findings/Techniques
Prostate imaging, PET/CT, and theranostics.
Conclusion
Molecular imaging is a rapidly evolving field with newer imaging agents targeted towards prostate cancer and many others currently under investigations. Radiology trainees should be familiar with the available imaging probes, their utility, and their normal distribution. Similarly, theranostics is a budding field with a lot of potential, and familiarity with the available theranostic agents is crucial for trainees.
